💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Trihexyphenidyl

CHEMBL1490 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
301.5 g/mol
LogP
4.5
Phase
4

Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the striatum, restoring dopamine-acetylcholine balance disrupted by nigrostriatal dopamine depletion in Parkinson's disease and drug-induced parkinsonism. It is used to reduce tremor, rigidity, and sialorrhea in Parkinson's disease and for treatment of extrapyramidal symptoms caused by antipsychotic medications. Its CNS anticholinergic effects can cause cognitive impairment, hallucinations, and confusion, particularly in elderly patients, limiting its use in modern Parkinson's disease management.

分子量

301.5000 g/mol

LogP

4.50

TPSA

23.50 Ų

リピンスキーの五則

適合

治療領域

Pain Management Schizophrenia Bipolar Disorder Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1

                

                

                
                

                    
InChI

                    
InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H31NO

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
回転可能結合数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the striatum, restoring dopamine-acetylcholine balance disrupted by nigrostriatal dopamine depletion in Parkinson's disease and drug-induced parkinsonism. It is used to reduce tremor, rigidity, and sialorrhea in Parkinson's disease and for treatment of extrapyramidal symptoms caused by antipsychotic medications. Its CNS anticholinergic effects can cause cognitive impairment, hallucinations, and confusion, particularly in elderly patients, limiting its use in modern Parkinson's disease management.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Trihexyphenidyl is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1490.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5572.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.